Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Poorly soluble photosensitizer, meso-tetraphenylporphine (TPP), was solubilized using the polymeric micelles prepared from polyethylene glycol-phosphatidyl ethanolamine conjugate (PEG-PE). TPP-loaded PEG-PE micelles have been additionally modified with tumor-specific monoclonal 2C5 antibody (mAb 2C5), which resulted in significantly improved anticancer effect of the drug under the PDT conditions against murine Lewis lung carcinoma (LLC) In vivo in female C57BL/6 mice. Fourteen days after tumor inoculation, the mice with more than 2 mm diameter tumors were given an intravenous injection of 1 mg/kg of free TPP or TPP loaded into control PEG-PE micelles or into mAb 2C5-PEG-PE tumor-targeted immunomicelles. Twenty-four hours after the administration, the animals were anesthetized, and tumor sites were illuminated with light (630 nm) for 12 min. Microscopic evaluation of tumor response was conducted in some mice 24 h after light irradiation, and tumor size was followed in the remaining animals for another 35 days. The attachment of mAb 2C5 to TPP-loaded immunomicelles provided the maximum level of tumor growth inhibition. Enhanced tumor accumulation of TPP-loaded mAb 2C5-PEG-PE-immunomicelles was confirmed by gamma-imaging studies. The modification of the TPP-loaded polymeric micelles with tumor-specific antibodies could be used as a general approach to enhance the efficacy of PDT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Block copolymer micelles: preparation, characterization and application in drug delivery
Gaucher, G., Dufresne, M.-H., Sant, V. P., Kang, N., Maysinger, D., & Leroux, J.-C. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.034 · Cited by 1,498
Cited by
Functional Nanomaterials for Phototherapies of Cancer
Cheng, L., Wang, C., Feng, L., Yang, K., & Liu, Z. (2014) · Chemical Reviews · doi:10.1021/cr400532z · Cited by 2,425
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
Torchilin, V. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.026 · Cited by 583
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript tumor photo-dynamic therapy (PDT) both to multiple cancer cells in vitro and to experimental tumors in vivo and provide a significantly enhanced tumor cell killing under the conditions of PDT [67].”
BackgroundSelf-citationNanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer
Gurunathan, S., Kang, M.-H., Qasim, M., & Kim, J.-H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103264 · Cited by 367
“Similarly, the authors studied TPP-loaded PEG-PE micelles using a tumor-specific monoclonal 2C5 antibody, which resulted in a significantly improved anticancer effect of the drug under the PDT conditions against murine LLC cells in female C57BL/6 mice [98].”
BackgroundNanodrug applications in photodynamic therapy
Paszko, E., Ehrhardt, C., Senge, M. O., Kelleher, D. P., & Reynolds, J. V. (2011) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2010.12.001 · Cited by 356
Micelles structure development as a strategy to improve smart cancer therapy
Hanafy, N., El-Kemary, M., & Leporatti, S. (2018) · Cancers · doi:10.3390/cancers10070238 · Cited by 287
“In clinical trials, NK911 and SP1049C [104] and NK105 and NC6004 are currently passed to Phases I and II [106,107].”
Background
Metadata
- Authors
- Roby, A., Erdogan, S., & Torchilin, V. P.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2007-07-11
- Volume
- 6
- Issue
- 7
- Pages
- 1136-1142
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2055951605
- Cited by
- 69
- References
- 1
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles. https://app.cochat.ai/papers/10.4161/cbt.6.7.4345
- The paper
- Roby, A., Erdogan, S., & Torchilin, V. P. (2007). Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles. Cancer Biology & Therapy. https://doi.org/10.4161/cbt.6.7.4345
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.